0001237899-14-000017.txt : 20140213
0001237899-14-000017.hdr.sgml : 20140213
20140213160332
ACCESSION NUMBER: 0001237899-14-000017
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20140211
FILED AS OF DATE: 20140213
DATE AS OF CHANGE: 20140213
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER RD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591-6707
BUSINESS PHONE: 9143477000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YANCOPOULOS GEORGE
CENTRAL INDEX KEY: 0001226690
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 14605994
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2014-02-11
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001226690
YANCOPOULOS GEORGE
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
1
0
0
President Regeneron Laboratori
Common Stock
2014-02-11
4
M
0
189463.0
9.49
A
1257806
D
Common Stock
2014-02-11
4
F
0
5720.0
314.31
D
1252086
D
Common Stock
2014-02-11
4
F
0
94756.0
314.31
D
1157330
D
Common Stock
2014-02-12
4
S
0
4322.0
317.82
D
1153008
D
Common Stock
2014-02-12
4
S
0
15816.0
318.52
D
1137192
D
Common Stock
2014-02-12
4
S
0
30858.0
319.44
D
1106334
D
Common Stock
2014-02-12
4
S
0
17274.0
320.48
D
1089060
D
Common Stock
2014-02-12
4
S
0
8021.0
321.48
D
1081039
D
Common Stock
2014-02-12
4
S
0
3874.0
322.34
D
1077165
D
Common Stock
2014-02-12
4
S
0
1490.0
323.42
D
1075675
D
Common Stock
2014-02-12
4
S
0
1700.0
324.61
D
1073975
D
Common Stock
2014-02-12
4
S
0
1932.0
325.44
D
1072043
D
Common Stock
2014-02-12
4
S
0
2100.0
326.36
D
1069943
D
Common Stock
2014-02-12
4
S
0
600.0
327.88
D
1069343
D
Common Stock
2014-02-12
4
S
0
1000.0
328.5
D
1068343
D
Common Stock
5623
I
By 401(k) Plan
Non-Qualified Stock Option (right to buy)
9.49
2014-02-11
4
M
0
189463.0
0.0
D
2014-12-15
Common Stock
189463
0
D
Non-Qualified Stock Option (right to buy)
314.31
2014-02-11
4
A
0
5720.0
0.0
A
2014-08-11
2014-12-15
Common Stock
5720
5720
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
Represents volume-weighted average price of sales of 4,322 shares of Company stock on February 12, 2014 at prices ranging from $317.70 to $317.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 15,816 shares of Company stock on February 12, 2014 at prices ranging from $318.00 to $318.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 30,858 shares of Company stock on February 12, 2014 at prices ranging from $319.00 to $319.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 17,274 shares of Company stock on February 12, 2014 at prices ranging from $320.00 to $320.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 8,021 shares of Company stock on February 12, 2014 at prices ranging from $321.00 to $321.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 3,874 shares of Company stock on February 12, 2014 at prices ranging from $322.18 to $322.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 1,490 shares of Company stock on February 12, 2014 at prices ranging from $323.00 to $323.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 1,700 shares of Company stock on February 12, 2014 at prices ranging from $324.50 to $324.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 1,932 shares of Company stock on February 12, 2014 at prices ranging from $325.10 to $325.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 2,100 shares of Company stock on February 12, 2014 at prices ranging from $326.00 to $326.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
Represents volume-weighted average price of sales of 1,000 shares of Company stock on February 12, 2014 at prices ranging from $328.17 to $328.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.
The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
By: Beverly Dubs For: /s/**George D. Yancopoulos
2014-02-13
EX-24
2
bny13229_bny1gy.txt
EDGAR SUPPORTING DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Leonard Schleifer, , Beverly Dubs, Stuart Kolinski, Murray
Goldberg, and Douglas McCorkle signing singly, the undersigned's true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned in the undersigned's
capacity as a director of Regeneron Pharmaceuticals, Inc. (the
"Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of
the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such
Form 3, 4, or 5, complete and execute any amendment or amendments
thereto, and timely file such form with the United States Securities
and Exchange Commission and any stock exchange or similar authority;
and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-act on behalf of the undersigned pursuant to this Power
of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 9th day of September, 2005.
**/s/George Yancopoulos
-----------------------
Signature
George Yancopoulos
------------------
Print Name